Clinical and preclinical evidence highlight the efficacy of intranasal insulin (INI) in treating Alzheimer's disease (AD) and delirium, with studies showing significant improvements in cognitive scores and reduced hospital stays (7.9 vs. 12.9 days; <i>p</i> = 0.014). This evidence concerns the gene INS and delirium.